Generex’s filings don’t show any milestone pay
Post# of 36566
(Total Views: 117)
Posted On: 01/14/2019 8:30:09 PM
Generex’s filings don’t show any milestone payments from Merck. The study costs AE $2.18 million, with the payment periods illustrated in the 8k filing:
https://www.sec.gov/Archives/edgar/data/10597...ex10_1.htm
The completed AE37 Phase II had promising results in the triple negative subgroup, but there weren’t many subjects. AE37 overall looks better in low her2 expressor patients, and obviously the bigger issue with higher expressing 3+ subjects is the control received Herceptin. Because previous powers that be enrolled too many of these subjects, the overall Phase II results were hampered. But, the fault there lays with the USMCI group. Clinical benefit is certainly evident, and statistically significant in the triple negative subgroup, and AE37 now appears positioned for success.
Antigen Express was once valued at $300+ million, quite a few years ago. With a successful study result, or interim, value will strikingly increase. I’d target that older valuation as a goal. The billion dollar talk is something we’d all like to see, but NuGenerex Immuno-Oncology will work towards that high of a marker. Antigen had been relatively dormant until recently, at least in the clinic. The partnership in China, the research collaboration with Merck, are big steps forward. The China deal will bring milestone payments which would be great news. The Merck deal could grow later bringing a finical commitment from Merck. New deals could be won. And then that higher valuation is earned.
Low floor, high ceiling.
https://www.sec.gov/Archives/edgar/data/10597...ex10_1.htm
The completed AE37 Phase II had promising results in the triple negative subgroup, but there weren’t many subjects. AE37 overall looks better in low her2 expressor patients, and obviously the bigger issue with higher expressing 3+ subjects is the control received Herceptin. Because previous powers that be enrolled too many of these subjects, the overall Phase II results were hampered. But, the fault there lays with the USMCI group. Clinical benefit is certainly evident, and statistically significant in the triple negative subgroup, and AE37 now appears positioned for success.
Antigen Express was once valued at $300+ million, quite a few years ago. With a successful study result, or interim, value will strikingly increase. I’d target that older valuation as a goal. The billion dollar talk is something we’d all like to see, but NuGenerex Immuno-Oncology will work towards that high of a marker. Antigen had been relatively dormant until recently, at least in the clinic. The partnership in China, the research collaboration with Merck, are big steps forward. The China deal will bring milestone payments which would be great news. The Merck deal could grow later bringing a finical commitment from Merck. New deals could be won. And then that higher valuation is earned.
Low floor, high ceiling.
(2)
(0)